http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1930308-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0f4a900d2d9308385d00e4c55a0114bd |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C217-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D295-03 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D295-088 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D211-90 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C43-164 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C43-1745 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D473-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C211-28 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-075 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D473-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-90 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C211-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D295-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D295-03 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D295-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D295-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C43-164 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C43-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C43-174 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C43-178 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-522 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C217-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-138 |
| filingDate | 1998-05-19^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ba742fc724b2067e6a208c98ebd2635a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_83852dc2a1c1624c80f965fdf2bd3115 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_13fd00f1cd1690d0f5c1b722bc67bf3b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_64e8e2372d2432ca7176ebf84b94e1e8 |
| publicationDate | 2008-06-11^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-1930308-A1 |
| titleOfInvention | Pharmaceutical agents for the treatment of cerebral amyloidosis |
| abstract | The invention relates to a compound of the following general formula (III):n nwherein: nR 1 and R 2 each are one or more independent substituents selected from the group consisting of hydrogen, C1-C5 alkyl, C2-C5 alkenyl, C3-C5 cycloalkyl, C1-C5 alkoxy, C2-C5 alkynyl, halogen, C1-C5 haloalkyl, alkylamino, phenyl, nitro and carboxyl; nR 3 is selected from the group consisting of amino, C1-C5 substituted amino and CH 2 ; nn and m are independently an integer of from 0-5; n nor a pharmaceutically acceptable salt of such compound; na compound of the following general formula (IV):n nwherein: nR 1 and R 2 each are one or more independent substituents selected from the group consisting of hydrogen, C1-C5 alkyl, C2-C5 alkenyl, C3-C5 cycloalkyl, C1-C5 alkoxy, C2-C5 alkynyl, halogen, C1-C5 haloalkyl, alkylamino, phenyl, nitro and ca rboxyl; nR 3 and R 4 each are independent and selected from the group consisting of hydrogen and C1-C5 alkyl; nn is an integer of from 1 to 5; n nor a pharmaceutically acceptable salt of such compound; na compound of the following general formula (V):n nwherein: nR 1 and R 2 each are one or more independent substituents selected from the group consisting of hydrogen, C1-C5 alkyl, C2-C5 alkenyl, C3-C5 cycloalkyl, C1-C5 alkoxy, C2-C5 alkynyl, halogen, C1-C5 haloalkyl, alkylamino, phenyl, nitro and carboxyl; nR 3 is selected from hydrogen and C1-C5 alkyl; nR 4 is selected from hydrogen and C1-C5 alkyl; nn is an integer of from 1 to 5 inclusive; nor a pharmaceutically acceptable salt of such compound; and na compound of the following general formula (VI):n nwherein: nR 1 and R 2 each are one or more independent substituents selected from the group consisting of hydrogen, C1-C5 alkyl, C2-C5 alkenyl, C3-C5 cycloalkyl, C1-C5 alkoxy, C2-C5 alkynyl, halogen, C1-C5 haloalkyl, alkylamino, phenyl, nitro and carboxyl; nR3 and R4 each are independent and selected from hydrogen and C1-C5 alkyl; nn is an integer of from 1 to 5 inclusive; nor a pharmaceutically acceptable salt of such compound. n Also compositions comprising the compounds III-VI as well as uses of said compounds. |
| priorityDate | 1997-05-19^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 622 of 622.